Hawk, a preeminent Native American public health expert, discusses RSV, “data genocide” and positive change driven by ...

Every year, viral respiratory infections place a significant burden on the health care system. The CDC predicts that influenza, respiratory syncytial virus and COVID-19 collectively will account for ...

Crisp weather is popping up across the United States, signalling the start of fall, a new school year and, of course, respiratory virus season. But five years after the emergence of the COVID-19 ...

In late summer, tens of millions of children throughout the United States return to school, sharing tales of their summer adventures and, inevitably, new germs. Many will develop a cough, sore throat, ...

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on September 4, 2025 the Company received notification from The Nasdaq ...

Your medicine cabinet could be packing more than just cold and flu relief. A groundbreaking new study found that a widely available over-the-counter nasal spray may help healthy adults fend off ...

In 2025, GSK expects to launch five new products/line extensions, including Blenrep, depemokimab (severe asthma and CRSwNP), Nucala for COPD, Penmenvy and Blujepa. Of these, Penmenvy, Blujepa and ...

L1, Keytruda, approaches loss of exclusivity (LOE) in 2028. The drug is the company's biggest revenue driver, accounting for ...

Respiratory syncytial virus (RSV) can cause serious illness in older adults. The bivalent RSV prefusion F protein–based vaccine (RSVpreF) has been shown to prevent RSV-associated respiratory illness, ...

In mid-September, the CDC’s Advisory Committee on Immunization Practices will discuss — and potentially vote on — vaccines for COVID-19, hepatitis B, measles, mumps, rubella, varicella, and ...

Citing a “new evidenced based philosophy,” the FDA’s Center for Biologics Evaluation and Research (CBER) is preparing to take a hard line against the common practice of administering certain ...